Lin, Wei-ChenWei-ChenLinTai, Wei-ChenWei-ChenTaiChang, Chung-HsinChung-HsinChangCHIA-HUNG TUFeng, I-CheI-CheFengMING-JIUM SHIEHChung, Chen-ShuanChen-ShuanChungYen, Hsu-HengHsu-HengYenChou, Jen-WeiJen-WeiChouJAU-MIN WONGLiu, Yu-HwaYu-HwaLiuHuang, Tien-YuTien-YuHuangChuang, Chiao-HsiungChiao-HsiungChuangTsai, Tzung-JiunTzung-JiunTsaiChiang, Feng-FanFeng-FanChiangLu, Chien-YuChien-YuLuHsu, Wen-HungWen-HungHsuYu, Fang-JungFang-JungYuChao, Te-HsinTe-HsinChaoWu, Deng-ChyangDeng-ChyangWuHo, Ai-ShengAi-ShengHoLin, Hung-HsinHung-HsinLinFeng, Chun-LungChun-LungFengWu, Keng-LiangKeng-LiangWuWong, Ming-WunMing-WunWongCHIEN-CHIH TUNGLin, Chun-ChiChun-ChiLinChen, Chia-ChangChia-ChangChenHu, Huang-MingHuang-MingHuLu, Lung-ShengLung-ShengLuWang, Huann-ShengHuann-ShengWangWu, I-ChenI-ChenWuKuo, Hsin-YuHsin-YuKuoJIA-FENG WUYao Shih, HsiangHsiangYao ShihTang, Shu-LunShu-LunTangChen, Peng-HsuPeng-HsuChenYEN-HSUAN NISHU-CHEN WEI2023-11-252023-11-252023-11-021078-09981536-4844https://scholars.lib.ntu.edu.tw/handle/123456789/637378This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.enCrohn’s disease; reimbursement; ulcerative colitis; vedolizumab[SDGs]SDG3journal article10.1093/ibd/izac269366265672-s2.0-85156110463